本报告导读：公司三大板块均良性发展，盈利状况进一步改善，联营公司传奇生物CART 放量提速，预计 2026年盈利，有望给母公司贡献利润，维持“增持”评级。投资要点：维持“增持”评级。2024年公司持续经营业务收入5.95 亿美元（+6.1%）；集团净利润达到约29 亿美元，实现扭亏为盈，主要系解除合并传奇生物所带来的一次性投资收益（32 亿美金）；报告期内持续经营业务的经调整净利润保持稳定，约...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.